Cargando…

Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review

This review presents the most common disease entities in which combinations of NSAIDs and spasmolytic drugs are used to reduce pain. The benefits of fixed-dose combination products (FDCs) are that they improve the response in people with insufficient monotherapy. Using the synergy or additive effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Janczura, Magdalena, Kobus-Moryson, Małgorzata, Sip, Szymon, Żarowski, Marcin, Wareńczak, Agnieszka, Cielecka-Piontek, Judyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306558/
https://www.ncbi.nlm.nih.gov/pubmed/34300284
http://dx.doi.org/10.3390/jcm10143118
_version_ 1783727839564005376
author Janczura, Magdalena
Kobus-Moryson, Małgorzata
Sip, Szymon
Żarowski, Marcin
Wareńczak, Agnieszka
Cielecka-Piontek, Judyta
author_facet Janczura, Magdalena
Kobus-Moryson, Małgorzata
Sip, Szymon
Żarowski, Marcin
Wareńczak, Agnieszka
Cielecka-Piontek, Judyta
author_sort Janczura, Magdalena
collection PubMed
description This review presents the most common disease entities in which combinations of NSAIDs and spasmolytic drugs are used to reduce pain. The benefits of fixed-dose combination products (FDCs) are that they improve the response in people with insufficient monotherapy. Using the synergy or additive effect of drugs, it is possible to obtain a significant therapeutic effect and faster action with the use of smaller doses of individual drugs. In addition, one active ingredient may counteract adverse reactions from the other. Another essential aspect of the use of FDCs is the improvement of medical adherence due to the reduction in the pill burden on patients. It is also possible to develop a fixed-dosed combination product de novo to address a new therapeutic claim and be protected by patents so that the manufacturer can obtain exclusive rights to sell a particular FDC or a formulation thereof. The proposed fixed-dose combinations should always be based on valid therapeutic principles and consider the combined safety profile of all active substances included in the medicinal product. This review aims to identify which combinations of NSAIDs and spasmolytics have been developed and tested and which combinations are still under development.
format Online
Article
Text
id pubmed-8306558
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83065582021-07-25 Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review Janczura, Magdalena Kobus-Moryson, Małgorzata Sip, Szymon Żarowski, Marcin Wareńczak, Agnieszka Cielecka-Piontek, Judyta J Clin Med Review This review presents the most common disease entities in which combinations of NSAIDs and spasmolytic drugs are used to reduce pain. The benefits of fixed-dose combination products (FDCs) are that they improve the response in people with insufficient monotherapy. Using the synergy or additive effect of drugs, it is possible to obtain a significant therapeutic effect and faster action with the use of smaller doses of individual drugs. In addition, one active ingredient may counteract adverse reactions from the other. Another essential aspect of the use of FDCs is the improvement of medical adherence due to the reduction in the pill burden on patients. It is also possible to develop a fixed-dosed combination product de novo to address a new therapeutic claim and be protected by patents so that the manufacturer can obtain exclusive rights to sell a particular FDC or a formulation thereof. The proposed fixed-dose combinations should always be based on valid therapeutic principles and consider the combined safety profile of all active substances included in the medicinal product. This review aims to identify which combinations of NSAIDs and spasmolytics have been developed and tested and which combinations are still under development. MDPI 2021-07-15 /pmc/articles/PMC8306558/ /pubmed/34300284 http://dx.doi.org/10.3390/jcm10143118 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Janczura, Magdalena
Kobus-Moryson, Małgorzata
Sip, Szymon
Żarowski, Marcin
Wareńczak, Agnieszka
Cielecka-Piontek, Judyta
Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
title Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
title_full Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
title_fullStr Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
title_full_unstemmed Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
title_short Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
title_sort fixed-dose combination of nsaids and spasmolytic agents in the treatment of different types of pain—a practical review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306558/
https://www.ncbi.nlm.nih.gov/pubmed/34300284
http://dx.doi.org/10.3390/jcm10143118
work_keys_str_mv AT janczuramagdalena fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview
AT kobusmorysonmałgorzata fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview
AT sipszymon fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview
AT zarowskimarcin fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview
AT warenczakagnieszka fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview
AT cieleckapiontekjudyta fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview